• Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    May 14, 2014 Study highlights VeriStrat®’s ability to predict differential treatment outcomes between erlotinib and chemotherapy for non-small cell lung cancer Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the publication of results from the investigator-initiated study, “Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable ... Read more
  • AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC

    April 10, 2014 Biodesix to Fund Proof of Concept Study  AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®, a serum protein test ... Read more
  • Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

    March 3, 2014 Blood-based protein diagnostic predicts differential treatment outcomes for non-small cell lung cancer Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that it has obtained the CE Mark for its VeriStrat® specimen collection and shipping kit, clearing the company to make VeriStrat results available to physicians in the European Union and ... Read more
  • Biodesix and Capital Royalty Close Financing Transaction

    February 12, 2014 Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed a structured debt financing with Capital Royalty Partners L.P.  The transaction provides Biodesix®with up to $20 million of capital. “Capital Royalty’s financing structure has been uniquely tailored to suit our capital needs, especially during this growth phase of ... Read more
  • Biodesix Adds to Series E Financing

    January 13, 2014 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company increased the size of its recent offering of series E preferred shares in a follow-on sale. In addition to the $8.3 million of series E shares sold a month ago, the company brought in another $6.1 million, for ... Read more
  • Biodesix Closes Series E Financing

    December 3, 2013 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed an $8.3 million Series E preferred equity financing. New funds accounted for $4.3 million of the round and the remaining $4 million came from the conversion of a convertible note. Existing Biodesix shareholders provided all of the ... Read more
  • Biodesix to Present at World CDx

    November 15, 2013 Session Examines Use of Proteomics and Mass Spec to Improve Biomarker Validation BOSTON AND BOULDER, Colo.– November 13, 2013 – Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Vice President of Business Development and Strategic Marketing, Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013. ... Read more
  • Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat®. Results were presented at the 15thWorld Conference on Lung Cancer in Sydney, Australia. “PROSE data confirms VeriStrat can predict differential treatment outcomes in second-line advanced NCLSC patients; VeriStrat is ... Read more
  • Biodesix Secures Medicare Coverage for VeriStrat Test

    June 20, 2013 Coverage of Predictive Biomarker Test Enables Lung Cancer Patients to Benefit From More-Informed Treatment Decisions Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that Novitas Solutions, the Medicare Administrative Contractor for the region that includes Colorado, has established coverage for the company’s VeriStrat test. VeriStrat, a clinically validated blood-based protein test, helps physicians ... Read more
  • Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    June 3, 2013 Results of independent trial confirm VeriStrat’s ability to predict differential treatment outcomes between erlotinib and chemotherapy Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced results of the recently completed phase III clinical trial for its VeriStrat® test. Data confirms that the non-invasive, blood-based protein diagnostic is predictive of differential treatment outcomes ... Read more